Physician profile
Steven E Barnes
NPI 1295758860
$4,747.50
in general payments reported to CMS, 2019-2025
33 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $160 · 2021: $204 · 2022: $1,401 · 2023: $1,971 · 2024: $664 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.40 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $562.74 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $495.41 | 2021-2024 | Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $438.26 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $330.49 | 2019-2024 | Farxiga, Lokelma, Breztri |
| Lilly USA, LLC | $302.58 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $271.93 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.36 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Astellas Pharma US INC | $233.41 | 2022-2024 | Veozah, Myrbetriq |
| Boston Scientific Corporation | $210.39 | 2022-2025 | Watchman Flx |
| Amgen INC. | $201.69 | 2022-2024 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $198.92 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $174.82 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $139.40 | 2022-2024 | Verquvo, Steglatro, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.04 | 2020-2024 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $100.03 | 2024 | Gemtesa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $98.44 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $95.93 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $91.21 | 2022-2024 | Xarelto |
| Sunovion Pharmaceuticals INC. | $85.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.26 | 2022 | |
| Dexcom, INC. | $39.66 | 2023-2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $34.17 | 2023-2024 | Yupelri |
| Impulse Dynamics (USA) INC. | $29.33 | 2025 | Optimizer |
| Daiichi Sankyo INC. | $25.98 | 2022 | |
| Abbott Laboratories | $23.22 | 2022 | |
| Edwards Lifesciences Corporation | $21.17 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Advanced Oxygen Therapy INC. | $20.75 | 2023 | Topical Oxygen Chamber For Extremities |
| Shield Therapeutics INC | $19.97 | 2023 | Accrufer |
| Paratek Pharmaceuticals, INC. | $19.90 | 2023 | Nuzyra |
| Lundbeck LLC | $16.64 | 2023 | Rexulti |
| Almatica Pharma LLC | $15.24 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.96 | 2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $13.98 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.